Trader Alert --- AVII

Opened a position in AVI BioPharma Inc

AVI BioPharma, Inc., a biopharmaceutical company, engages in the development
of therapeutic products based on NEUGENE antisense technology. Its principal
products in development target life-threatening diseases, including
cardiovascular disease, infectious disease, and cancer. AVI’s lead product
candidate, Resten-NG, is a NEUGENE antisense drug for treating
cardiovascular restenosis, or the re-narrowing of a coronary artery
following angioplasty. In addition to targeting specific genes in the body,
AVI’s antiviral program uses NEUGENE antisense compounds to combat disease
by targeting single–stranded RNA viruses, including West Nile virus,
hepatitis C virus, dengue virus, and Ebola virus. AVI has also evaluated
Avicine, a therapeutic cancer vaccine, in six clinical trials involving
colorectal and pancreatic cancer; completed Phase Ib/II trials of AVI-4557
targeting drug metabolism; and evaluated Phase I trials of AVI-4126
targeting polycystic kidney disease. The company has strategic alliances
with SuperGen, Inc.; Medtronic, Inc.; and Exelixis, Inc. AVI was
incorporated in 1980 as Antivirals, Inc. and changed its name to AVI
BioPharma, Inc. in 1998. AVI is based in Portland, Oregon.

Re: Trader Alert --- AVII

I own some ev3 check it out.

<EVVV>

Re: Trader Alert --- AVII

Thanks for your stock tips, nice looking chart and if closed above today's
high $16.72 will be bullish looking forward. I will keep it on my shopping
list. Thanks again.

--
Vincent


<> wrote in message
news:
> I own some ev3 check it out.
>
> <EVVV>
>